Cezary Cybulski
Overview
Explore the profile of Cezary Cybulski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
295
Citations
8277
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Kang E, Weir A, Meagher N, Farrington K, Nelson G, Ghatage P, et al.
Cancer
. 2022 Dec;
129(5):697-713.
PMID: 36572991
Background: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression...
32.
Rowinska K, Baszuk P, Rogoza-Janiszewska E, Deptula J, Marciniak W, Derkacz R, et al.
Biomedicines
. 2022 Dec;
10(12).
PMID: 36551774
The malignant melanoma of the skin is a very aggressive tumor. The determination of prognostic biomarkers is important for the early detection of recurrence, and for the enrollment of the...
33.
Weir A, Kang E, Meagher N, Nelson G, Ghatage P, Lee C, et al.
Br J Cancer
. 2022 Nov;
128(1):137-147.
PMID: 36323878
Background: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied...
34.
Meagher N, Gorringe K, Wakefield M, Bolithon A, Pang C, Chiu D, et al.
Clin Cancer Res
. 2022 Oct;
28(24):5383-5395.
PMID: 36222710
Purpose: Advanced-stage mucinous ovarian carcinoma (MOC) has poor chemotherapy response and prognosis and lacks biomarkers to aid stage I adjuvant treatment. Differentiating primary MOC from gastrointestinal (GI) metastases to the...
35.
Finch A, Clark R, Vesprini D, Lorentz J, Kim R, Thain E, et al.
NPJ Precis Oncol
. 2022 Jun;
6(1):43.
PMID: 35732815
Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of prostate cancer, in particular cases with metastatic disease are selected. Advances in the field are expected...
36.
Mahmoodi A, Shoqafi A, Sun P, Giannakeas V, Cybulski C, Nofech-Mozes S, et al.
Front Oncol
. 2022 Jun;
12:877617.
PMID: 35712517
Background: RECQL (also known as RECQ1 and RECQL1) is a gene of recent interest in breast cancer and an association between high levels of RECQL protein in breast cancer tumour...
37.
Kluzniak W, Szymiczek A, Rodrigue A, Wokolorczyk D, Rusak B, Stempa K, et al.
JCO Precis Oncol
. 2022 Apr;
6:e2100450.
PMID: 35442721
Purpose: The p.K3326* variant is considered a low-penetrance variant for breast cancer. Aldehydes that accumulate in cells under insufficient aldehyde oxidation were most recently shown to trigger carcinogenesis by promoting...
38.
Jasiewicz A, Rudnicka H, Kluzniak W, Gronwald W, Kluz T, Cybulski C, et al.
Hered Cancer Clin Pract
. 2022 Apr;
20(1):12.
PMID: 35382848
Background: Mutations in BRCA1 and BRCA2 genes are well-established risk factors of breast and ovarian cancer. In our former study, we observed that approximately 6% of unselected ovarian cancer patients...
39.
Ogrodniczak A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Cybulski C, et al.
Hered Cancer Clin Pract
. 2022 Mar;
20(1):11.
PMID: 35313928
Background: There are several genes associated with ovarian cancer risk. Molecular changes in borderline ovarian tumor (BOT) indicate linkage of this disease to type I ovarian tumors (low-grade ovarian carcinomas)....
40.
Tomiczek-Szwiec J, Szwiec M, Falco M, Cybulski C, Wokolorczyk D, Jakubowska A, et al.
Br J Cancer
. 2022 Mar;
127(1):84-91.
PMID: 35256754
Background: To estimate the impact of oophorectomy and other treatments on the survival of breast cancer patients with a CHEK2 mutation. Methods: Women with Stage I-III breast cancer who were...